Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options
Authors:
Open Access
- 28 December 2022
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 28 (48) , 6827-6845
Abstract
Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment optionsKeywords
This publication has 161 references indexed in Scilit:
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has FailedJournal of Clinical Oncology, 2015
- Update on the management of pancreatic cancer: Surgery is not enoughWorld Journal of Gastroenterology, 2015
- Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker resultsInternational Journal of Clinical Oncology, 2014
- Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancerCancer Immunology, Immunotherapy, 2014
- A concise review on the current understanding of pancreatic cancer stem cellsJournal of Cancer Stem Cell Research, 2014
- Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort studyGut, 2012
- FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine TumorsThe Oncologist, 2012
- A New Mechanism of Action for the Anticancer Drug Mitomycin C: Mechanism-Based Inhibition of Thioredoxin ReductaseChemical Research in Toxicology, 2012
- Epidermal Growth Factor Receptor in Pancreatic CancerCancers, 2011
- The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancerEuropean Journal of Surgical Oncology, 2005